Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Dru... ( LONDON March 13 /- Silence Therap...)

Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery

Date:3/13/2008

LONDON, March 13 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) today announces a collaboration with AstraZeneca (LSE: AZN), focused on the development of a range of novel approaches for the delivery of siRNA molecules. The deal builds on Silence Therapeutics' leading expertise in the delivery of siRNA molecules, in particular its success with the functional systemic delivery of siRNA in vivo using its proprietary AtuPLEX technology. The financial details of this collaboration, in which both parties will contribute expertise and know-how, have not been disclosed.

This new deal is independent of the parties' three-year collaboration signed in July 2007, whose aim is to develop novel siRNA therapeutics against specific targets exclusive to AstraZeneca.

As a result of today's agreement, Silence Therapeutics and AstraZeneca will work together to develop new and improved approaches for the delivery of siRNA molecules. The successful delivery of siRNA molecules to different tissue sites is critical to realize the exciting potential of siRNA to treat a broad range of diseases. Under the terms of the agreement both Silence Therapeutics and AstraZeneca will be allowed to commercialise the truly novel delivery systems that they develop together.

Jeff Vick, CEO of Silence Therapeutics, commenting on today's announcement said, "We are delighted to enter this new collaboration with AstraZeneca for the development of novel approaches for the delivery of siRNA molecules. This agreement highlights the significant progress we have made with our AtuPLEX platform, following our early realization of the importance of delivery to the development of successful RNAi therapeutics. This deal also reflects the strong working relationship we have developed with AstraZeneca and the progress of our ongoing collaboration in the development of AtuRNAi molecules against a number of their targets."

Mr. Vick continued, "We look forward to continuing
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
2. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
3. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
4. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
5. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
6. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
7. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
8. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
9. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
10. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
11. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference

Post Your Comments:

(Date:11/30/2009)...ewswire/ -- Acuo Technologies, developers of high-...a migration tools and services, today announced co...new Vendor Neutral Archive (VNA), providing the fo...k of hospitals, clinics and affiliates. ,, The ...es DICOM Services Grid(TM) Software. The Acuo VNA...

(Date:11/30/2009)...v. 30 Good Publication Practice 2 ...n of company-sponsored medical research, has been ...nal (BMJ). "The publication of GPP2 in BMJ is stro...ort and guidance for industry sponsored research a...viewed medical literature," said Chris Graf, Assoc...

(Date:11/30/2009)...ANGELES, Nov. 30 /PRNewswire-Asia-FirstCall/ --,Ch...ard: CYXN; ,China Yongxin,Pharmaceuticals, or ,the...d,retailer of pharmaceuticals in Northeastern Chin...r distribution of medicines on the Essential Drug ...ormalized the nation,s Essential Drug,List which c...

(Date:11/30/2009)...roviding smart and efficient software to the precl... evolutionizing work-from-home histopathology by u...ware used by 8 of the Top 10 Pharmaceutical Compan...squo; basis. , Mount Arli...ounced another evolution in the histopathology rea...

Breaking Biology Technology:Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2 Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3 ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2 ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3 China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2 China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3 Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2 Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3

[0] Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics [1] ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ [0] China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List [0] Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS

...Calif., Feb. 9 Beckman Coulter, Inc. (NYSE: BEC...er of products that simplify, automate and innovat...th quarter and year ended December 31, 2008 result....3 million, up 2.8%, on robust sales to Clinical D...e in Life Sciences revenue. In constant currency,...

...Calif., Feb. 9 Beckman Coulter, Inc. (NYSE: BEC...lared a quarterly dividend payout of seventeen cen...payable on March 6, 2009 to all stockholders of re... the 79th consecutive, quarterly payout of dividen...rnh/20031202/BECLOGO ) , , Beckman Coulter, Inc.,...

... M2S Inc., a global provider of image man... device clinical trials, announced today that the ...ss how state-of-the-art image management can enhan...assurance services for bone mineral density trials...sition measurements with DXA. , ...

Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert

(Date:12/1/2009)...nnas aren,t just for listening to the radio anymor...GPS devices. Research from North Carolina State Un...esign creating shape-shifting antennas that open ...rom public safety to military deployment. , Mode...but there are limitations to how far they can be b...

(Date:11/30/2009)...rst comprehensive review of the state of Antarctic...mate system is published this week (Tuesday 1 Dece...earch (SCAR). The review - Antarctic Climate Chan...ch from the icy continent, identifies areas for fu... questions that policy makers have about Antarctic...

(Date:11/30/2009)... of scientists from The Forsyth Institute, the Uni...the Wadsworth Center, have used state-of-the-art t...of Treponema pallidum, the bacterium which causes ...e of the bacteria can now be shown in three dimens...thogen and reveals previously unknown features, wh...

Breaking Biology News(10 mins):Shape shifters: Researchers create new breed of antennas 2 First comprehensive review of the state of Antarctica's climate 2 Scientists gain new understanding of disease-causing bacteria 2 New Shape HF Cardiopulmonary Testing System to be on Display at the Heart Failure Society of America 13th Annual Scientific Meeting September 13 16 56506 1 New Shape HF Cardiopulmonary Testing System to be on Display at the Heart Failure Society of America 13th Annual Scientific Meeting September 13 16 56506 2 New Shape HF Cardiopulmonary Testing System to be on Display at the Heart Failure Society of America 13th Annual Scientific Meeting September 13 16 56506 3 First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 56504 1 First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 56504 2 First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 56504 3 Cell Therapeutics Inc s 28CTI 29 Rodman 26 Renshaw Healthcare Conference Presentation to be Webcast 56502 1

[0] Shape shifters: Researchers create new breed of antennas [0] First comprehensive review of the state of Antarctica's climate [0] Scientists gain new understanding of disease-causing bacteria

...prise the forests of the sea, and are responsible ...ins life on Earth including our own. However, unl...are nearly exclusively microscopic in size, and mo...ll in a very early stage of understanding even the...cology. , In a new paper published in Nature , a...

... variations in genes which can result in changes i... be associated with susceptibility to common disea...journal of the Association for Psychological Scien...es from the Karolinska Institutet in Sweden and th... effect of specific polymorphisms on how fear is l...

...rch 10, 2009) -- Virginia Commonwealth University ...chanism the malaria parasite uses to enter human r...t of a vaccine cocktail to fight the mosquito-born...ough bites from mosquitoes. According to the Cente... million and 500 million cases of malaria occur wo...

Other Biology News:A new view of oceanic phytoplankton 2 A new view of oceanic phytoplankton 3 The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders 2 Researchers identify new way the malaria parasite and red blood cells interact 2

A new view of oceanic phytoplankton The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders Researchers identify new way the malaria parasite and red blood cells interact

Factor Xa Protease from QIAGEN

Mung Bean Nuclease from New England Biolabs

...s for interferons are cytopathic effect inhibition...Sample types include; tissue culture supernatents;... In these assays, one unit is defined as the quant...e the cytopathic effect of viral infection by 50%....

SP6 RNA Polymerase from Roche Applied Science

Biology Products:

Factor Xa Protease from QIAGEN Mung Bean Nuclease from New England Biolabs Pig Interferon Alpha Bioassay Services from PBL InterferonSource SP6 RNA Polymerase from Roche Applied Science

Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Dru...( LONDON March 13 /- Silence Therap...)